natgillin/translations-raw huggingface dataset:
Overdose (symptoms, emergency procedures, antidotes): In case of overdose symptomatic treatment should be initiated. 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi): Pri nenamernem vnosu prevelikega odmerka uvedemo simptomatsko zdravljenje.
Polyethylene bottle containing 10 ml, 25 ml, 50 ml, 125 ml or 180 ml with a tamper proof child resistant closure and a polypropylene measuring syringe. 
Polietilenska plastenka po 10 ml, 25 ml, 50 ml, 125 ml ali 180 ml z varnostnim, za otroke varnim zapiralom in s polipropilensko merilno brizgo.
Disodium phosphate dodecahydrate Silica, colloidal anhydrous Hydroxyethylcellulose Citric acid monohydrate Sodium cyclamate Sucralose 
6.1 Seznam pomožnih snovi natrijev benzoat sorbitol glicerol polisorbat 80 natrijev hidrogefosfat dodekahidrat silicijev dioksid, koloidni, brezvodni hidroksietilceluloza citronska kislina monohidrat natrijev ciklamat sukraloza aroma janeža prečiščena voda
Sodium benzoate 1.75 mg. 
Pomožna snov: Natrijev benzoat 1,75 mg.
In case of overdose symptomatic treatment should be initiated. 
Pri nenamernem vnosu prevelikega odmerka uvedemo simptomatsko zdravljenje.
ANNEX I 
PRILOG I
The syringe should be stored in the carton box in between uses. 
Med dvema uporabama brizgo hranite v škatli.
Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. 
Ne uporabite pri mačkah z obolenji prebavil, kot so zdraženost prebavil in krvavitve, pri motnjah delovanja jeter, srca ali ledvic in pri hemoragičnih obolenjih.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS 
NAVEDBA UČINKOVIN(E) IN DRUGE(H) SESTAVIN En ml vsebuje:
MARKETING AUTHORISATION NUMBERS 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET
The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 
Na hitro izločanje kaže zaznavanje presnovkov iz izhodiščne spojine v urinu in blatu, ne pa tudi v plazmi.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. 
Občasno so poročali o značilnih neželenih učinkih nesteroidnih protivnetnih zdravil (NSAID), kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev), apatija in ledvična odpoved.
Shelf life after first opening the immediate packaging: 6 months. 
Rok uporabnosti po prvem odpiranju stične ovojnine: 6 mesecev.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. 
Ne uporabite pri psih z obolenji prebavil, kot so zdraženost prebavil in krvavitve, pri motnjah delovanja jeter, srca ali ledvic in pri hemoragičnih obolenjih.
Do not use in pregnant or lactating animals. 
Ne uporabite v obdobju brejosti ali laktacije.
In case of overdose, adverse reactions, as listed in section 6 "Adverse reactions", are expected to be more severe and more frequent. 
Pri prevelikem odmerjanju lahko pričakujemo resnejše in pogostejše neželene učinkih, opisane v poglavju 6.
Keep out of sight and reach of children. 
Shranjujte nedosegljivo otrokom.
Bottle of 5, 10 or 25 ml 
Plastenka s 5, 10 ali 25 ml
Each ml contains: Meloxicam 0.5 mg 
En ml vsebuje: meloksikam 0,5 mg
Bottle of 10, 25 or 50 ml 
Plastenke z 10, 25 ali 50 ml
Marketing authorisation holder: Le Vet B.V 
Imetnik dovoljenja za promet z zdravilom Le Vet B.V
Concurrent administration of potential nephrotoxic veterinary medicinal products should be avoided. 
Sočasnega dajanja zdravil za uporabo v veterinarski medicini, ki lahko imajo nefrotoksične učinke, se je treba izogibati.
A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE 
IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight. 
Zdravljenje nadaljujemo z enim peroralnim, vzdrževalnim odmerkom po 0,05 mg meloksikama na kilogram telesne mase na dan (v 24-urnih presledkih).
Each ml contains: Meloxicam 1.5 mg. 
En ml vsebuje: meloksikam 1,5 mg
Meloxicam 1.5 mg. 
Učinkovina: Meloksikam 1,5 mg.
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. 
Začetni odmerek prvi dan zdravljenja je 0,1 mg meloksikama na kilogram telesne mase peroralno.
Meloxicam 0.5 mg. 
Učinkovina: Meloksikam 0,5 mg.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. 
Posebni previdnostni ukrepi za uporabo pri živalih Zaradi nevarnosti toksičnih učinkov na ledvice se dajanju zdravila izogibamo pri dehidriranih, hipovolemičnih ali hipotenzivnih živalih.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. 
Zdravljenje nadaljujemo z enim peroralnim, vzdrževalnim odmerkom po 0,1 mg meloksikama na kilogram telesne mase na dan (v 24-urnih presledkih).
Meloxoral 0.5 mg/ml oral suspension for cats 
Meloxoral 0,5 mg/ml peroralna suspenzija za mačke
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. 
Meloksikam je nesteroidno protivnetno zdravilo (NSAID) iz skupine oksikamov.
In cats, Meloxoral 0.5 mg/ml oral suspension for cats should be used. 
Pri mačkah uporabljamo zdravilo Meloxoral 0,5 mg/ml peroralno suspenzijo za mačke.
Meloxoral 1.5 mg/ml oral suspension for dogs meloxicam 
Meloxoral 1,5 mg/ml peroralna suspenzija za pse meloksicam
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. 
Zaradi nevarnosti povečanih toksičnih učinkov na ledvice se dajanju zdravila izogibamo pri dehidriranih, hipovolemičnih ali hipotenzivnih živalih.
NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxoral 1.5 mg/ml oral suspension for dogs 
NAVODILO ZA UPORABO Meloxoral 1,5 mg/ml peroralna suspenzija za pse
PACKAGE LEAFLET: Meloxoral 0.5 mg/ml oral suspension for cats 
NAVODILO ZA UPORABO Meloxoral 0,5 mg/ml, peroralna suspenzija za mačke
Meloxoral 0.5 mg/ml oral suspension for cats meloxicam 
Meloxoral 0,5 mg/ml peroralna suspenzija za mačke meloksikam
Meloxoral 0.5 mg/ml oral suspension for cats Meloxicam 
Meloxoral 0,5 mg/ml, peroralna suspenzija za mačke Meloksikam
PACKAGE LEAFLET: Meloxoral 1.5 mg/ml oral suspension for dogs 
Meloxoral 1,5 mg/ml peroralna suspenzija za pse
The material is absorbed by the body in around 8 weeks. 
Material se v telesu absorbira v približno 8 tednih.
Evarrest fibrinogen / thrombin 
Evarrest fibrinogen/trombin
It must also not be used in patients with active infection or in contaminated areas. 
Poleg tega se ne sme uporabljati pri bolnikih z aktivno okužbo ali na kontaminiranih mestih.
The European Commission granted a marketing authorisation valid throughout the European Union for Evarrest on 25 September 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Evarrest, veljavno po vsej Evropski uniji, odobrila 25 septembra 2013.
The full EPAR for Evarrest can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Evarrest je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Evarrest? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Evarrest?
Other information about Evarrest 
Druge informacije o zdravilu Evarrest
This is a summary of the European public assessment report (EPAR) for Evarrest. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Evarrest.
It is made of absorbable material coated on one side with two active substances, fibrinogen and thrombin, and is available as 10.2 cm x 10.2 cm patches. 
Izdelano je iz absorbilnega materiala, ki je na eni strani obložen z dvema zdravilnima učinkovinama, fibrinogenom in trombinom, ter je na voljo v obliki obližev velikosti 10,2 cm x 10,2 cm.
However no more than two patches should be left in the patient as there has not been enough experience with larger quantities. 
Kljub temu lahko v telesu bolnika ostaneta največ dva obliža, saj je izkušenj z uporabo večjih količin premalo.
It should only be used in a single layer with an overlap of 1 to 2 cm on the surrounding non-bleeding tissue. 
Zdravilo se sme uporabiti samo v enem sloju in lahko sega približno 1 do 2 cm na okolno nekrvaveče tkivo.
It is not intended to provide practical advice on how to use Evarrest. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
A risk management plan has been developed to ensure that Evarrest is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Evarrest je bil pripravljen načrt obvladovanja tveganj.
The CHMP concluded that the benefits of Evarrest outweigh its risks and recommended that it be granted marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Evarrest večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Thrombin works by cutting fibrinogen up into smaller units called fibrin, which then stick together to form clots. 
Trombin deluje tako, da pretvori fibrinogen v manjše enote, imenovane fibrin, ki se nato sprimejo in tvorijo strdek.
The clots enable the patch to stick more firmly to the tissue thereby helping to stop the bleeding. 
Strdki omogočijo, da se obliž trdneje oprime tkiva in tako pomaga zaustaviti krvavitev.
Evarrest must not be used to repair the walls of large blood vessels, must not be applied to the inside of blood vessels and must not be used in closed spaces (such as openings in bones). 
Zdravilo Evarrest se ne sme uporabljati za popravilo poškodovanih sten velikih krvnih žil in ni primerno za vstavljanje v krvne žile, prav tako pa se ne sme uporabljati v zaprtih predelih (na primer v odprtinah v kosteh).
What is Evarrest and what is it used for? 
Kaj je zdravilo Evarrest in za kaj se uporablja?
What are the risks associated with Evarrest? 
Kakšna tveganja so povezana z zdravilom Evarrest?
What benefits of Evarrest have been shown in studies? 
Kakšne koristi je zdravilo Evarrest izkazalo v študijah?
Why is Evarrest approved? 
Zakaj je bilo zdravilo Evarrest odobreno?
The active substances in Evarrest, fibrinogen and thrombin, are proteins extracted from the blood, which are involved in the natural clotting process. 
Zdravilni učinkovini v zdravilu Evarrest, fibrinogen in trombin, sta beljakovini, pridobljeni iz krvi, ki sodelujeta pri naravnem procesu strjevanja krvi.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Evarrest, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Evarrest vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For more information about treatment with Evarrest, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Evarrest preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Evarrest should only be used by experienced surgeons who will judge the amount to use based on the size and location of the bleeding area. 
Zdravilo Evarrest lahko uporabljajo samo izkušeni kirurgi, ki bodo presodili, kakšno količino je primerno uporabiti glede na velikost in območje krvavečega mesta.
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Evarrest was shown to be effective when used to stop bleeding in surgery and the product could be a suitable alternative to other products and techniques. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je menil, da je bilo zdravilo Evarrest učinkovito pri zaustavljanju krvavitev med operacijo in da bi lahko bilo primerna alternativa drugim zdravilom in tehnikam.
Evarrest should therefore only be used when standard methods for controlling bleeding are not sufficient. 
Zato se lahko zdravilo Evarrest uporablja samo, kadar standardne metode za obvladovanje krvavitev niso dovolj učinkovite.
During surgery, the patches are cut to shape and size and used to seal off the bleeding area. 
Med operacijo se obliži razrežejo v želeno obliko in velikost ter se uporabijo za prekritje krvavečega mesta.
For practical information about using Evarrest, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Evarrest naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Evarrest is made of absorbable material that can be left in the patients after surgery. 
Zdravilo Evarrest je izdelano iz absorbilnega materiala, ki lahko po operaciji ostane v telesu bolnika.
Two studies compared Evarrest with commonly used surgical techniques considered to be standard care. 
V dveh študijah so zdravilo Evarrest primerjali s kirurškimi tehnikami, ki veljajo za standardno oskrbo.
Evarrest is a surgical product used in adults to help stop bleeding during surgery when standard methods for controlling bleeding are not sufficient. 
Evarrest je zdravilo za uporabo v kirurgiji, ki se uporablja pri odraslih za zaustavljanje krvavitev med operacijo, kadar standardne metode za obvladovanje krvavitev niso dovolj učinkovite.
For the full list of all side effects reported with Evarrest, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Evarrest, glejte navodilo za uporabo.
Evarrest has been shown in studies to be effective in helping to stop bleeding during surgeries, with most patients having their bleeding stopped within 4 minutes. 
Zdravilo Evarrest je v študijah učinkovito pomagalo zaustaviti krvavitve med operacijo, saj se je krvavitev pri večini bolnikov zaustavila v 4 minutah.
The complications that arise in patients being treated with Evarrest are generally related to the surgical procedure and the underlying conditions, and include post-surgery bleeding and increased fibrinogen levels in the blood. 
Zapleti, ki se lahko pojavijo pri bolnikih, zdravljenih z zdravilom Evarrest, so običajno povezani s kirurškim posegom in obstoječimi boleznimi ter vključujejo krvavitev po operaciji in zvišane ravni fibrinogena v krvi.
When an Evarrest patch is applied to a bleeding area during surgery, the moisture causes the active substances to react together, leading to the rapid formation of clots. 
Ko se zdravilo Evarrest med operacijo nanese na krvaveče mesto, vlaga povzroči, da zdravilni učinkovini reagirata med seboj in povzročita hitro tvorbo strdkov.
One study compared Evarrest with another product, Surgicel, in patients undergoing abdominal, thoracic and pelvic surgeries. 
V eni študiji so zdravilo Evarrest primerjali z drugim zdravilom, Surgicel, pri bolnikih, ki so prestali operacijo trebuha, prsnega koša in medenice.
How is Evarrest used? 
Kako se zdravilo Evarrest uporablja?
98% of the patients in the Evarrest group (59 out of 60) had their bleeding stopped within 4 minutes (with no recurrence of bleeding during a 6-minute observation period) compared with 53% of patients in the Surgicel group (16 out of 30). 
V skupini bolnikov, ki so prejeli zdravilo Evarrest, se je krvavitev v 4 minutah zaustavila pri 98 % (59 od 60) bolnikov (krvavitev se med 6-minutnim opazovanjem ni ponovila), v skupini, ki je prejela zdravilo Surgicel, pa pri 53 % (16 od 30) bolnikov.
The complications seen in studies with Evarrest were generally related the surgical procedure and the underlying conditions although there were cases of re-bleeding from the sites where Evarrest patches were used. 
Zapleti, ki so jih opazili med študijami z zdravilom Evarrest, so bili običajno povezani s kirurškim posegom in obstoječimi boleznimi, vendar pa so zabeležili tudi primere ponovne krvavitve na mestih, kjer so bili nameščeni obliži Evarrest.
Similar results were seen in a study in patients undergoing liver surgery: 83% of patients in the Evarrest group (33 out of 40) had their bleeding stopped within 4 minutes compared with 30% of the standard care group (13 out of 44). 
Podobne rezultate so zabeležili tudi v študiji z bolniki, ki so prestali operacijo jeter: v skupini, ki je prejela zdravilo Evarrest, se je krvavitev v 4 minutah zaustavila pri 83 % (33 od 40) bolnikov, v skupini, ki je bila deležna standardne oskrbe pa pri 30 % (13 od 44) bolnikov.
In a study in patients undergoing abdominal, thoracic and pelvic surgeries, 84% of patients in the Evarrest group had their bleeding stopped within 4 minutes (50 out of 59) compared with 31% (10 out of 32) in the standard care group. 
V študiji z bolniki, ki so prestali operacijo trebuha, prsnega koša in medenice, se je v skupini z zdravilom Evarrest krvavitev v 4 minutah zaustavila pri 84 % (50 od 59) bolnikov, v skupini s standardno oskrbo pa pri 31 % (10 od 32) bolnikov.
How does Evarrest work? 
Kako zdravilo Evarrest deluje?
Packaging Content Package sizeWithdrawal period 
Vsebina Velikost pakiranja
EU (MA) number 
EU (MA) številka
The main measure of effectiveness was the number patients who had a complete response to treatment. 
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se popolnoma odzvali na zdravljenje.
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Pixuvri on 10 May 2012. 
Evropska komisija je pogojno dovoljenje za promet z zdravilom Pixuvri, veljavno po vsej Evropski uniji, odobrila dne 10. maja 2012.
The side effects of the medicine were considered to be short term and manageable. 
Neželene učinke zdravila je opredelil kot kratkoročne in obvladljive.
It works by interfering with the DNA within cells, preventing them from making more copies of DNA and making proteins. 
Deluje tako, da zavira DNK v celicah, s čimer jim prepreči kopiranje DNK in izdelavo beljakovin.
The full EPAR for Pixuvri can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pixuvri je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In addition, patients treated with Pixuvri lived for longer without their disease getting worse. 
Poleg tega so bolniki, ki so se zdravili z zdravilom Pixuvri, živeli dlje, ne da bi se njihova bolezen poslabšala.
The recommended dose is 50 mg/m2 given as an infusion into a vein over at least 60 minutes on days 1, 8 and 15 of a 28-day cycle. 
Priporočeni odmerek je 50 mg/m2 v najmanj 60-minutni infuziji v veno, ki jo bolnik dobi 1., 8. in 15. dan 28-dnevnega kroga zdravljenja.
This is a summary of the European public assessment report (EPAR) for Pixuvri. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pixuvri.
It must not be used in patients with severe liver problems and in patients whose bone marrow produces abnormally low levels of blood cells. 
Ne smejo ga uporabljati bolniki, ki imajo hude težave z delovanjem jeter, in tisti, katerih kostni mozeg proizvaja neobičajno nizke ravni krvnih celic.
Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary. 
Evropska agencija za zdravila bo vsaj enkrat letno ponovno pregledala nove podatke o zdravilu in posodobila povzetek glavnih značilnosti zdravila, če bo potrebno.
The dose of Pixuvri is based on the patient's body surface area (calculated using the patient's height and weight). 
Odmerek zdravila Pixuvri temelji na bolnikovi telesni površini (izračunani na podlagi njegove višine in mase).
The effects of Pixuvri were first tested in experimental models before being studied in humans. 
Učinki zdravila Pixuvri so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
In patients who develop side effects or who have very low blood levels of neutrophils (a type of white blood cell that fights infection) and platelets (components that help the blood to clot), the dose may have to be reduced or treatment may have to be delayed. 
Pri bolnikih, pri katerih nastopijo neželeni učinki ali ki imajo v krvi zelo nizke ravni nevtrofilcev (vrste belih krvnih celic, ki se borijo proti okužbam) in krvnih ploščic (komponent, ki pomagajo pri strjevanju krvi), bo morda treba zmanjšati odmerek ali odložiti zdravljenje.
For more information about treatment with Pixuvri, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Pixuvri preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP concluded that the benefits of Pixuvri are greater than its risks and recommended that it be given marketing authorisation. 
Odbor CHMP je zaključil, da so koristi zdravila Pixuvri večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
EPAR summary for the public pixantrone 
Povzetek EPAR za javnost piksantron
It is available as a powder that is made up into a solution for infusion (a drip into a vein). 
Na voljo je kot prašek za pripravo raztopine za infundiranje (kapalne infuzije v veno).
The most common side effects with Pixuvri (seen in more than 1 patient in 10) are neutropenia, leucopenia and lymphopenia (low levels of different types of white blood cells), thrombocytopenia (low levels of platelets in the blood), anaemia (low levels of red blood cells), nausea (feeling sick), vomiting, skin discolouration, hair loss, chromaturia (abnormal colouration of the urine) and asthenia (weakness). 
Najpogostejši neželeni učinki zdravila Pixuvri (opaženi pri več kot 1 bolniku od 10) so nevtropenija, levkopenija in limfopenija (nizke ravni različnih vrst belih krvnih celic), trombocitopenija (nizke ravni krvnih ploščic), anemija (nizke ravni rdečih krvnih celic), navzeja (slabost), bruhanje, sprememba barve kože, izpadanje las, kromaturija (nenormalna obarvanost urina) in astenija (šibkost).
This means that there is more evidence to come about the medicine, in particular its benefits in patients who have previously been treated with rituximab. 
To pomeni, da se pričakujejo dodatni dokazi o zdravilu, zlasti o njegovih koristih pri bolnikih, ki so se prej zdravili z rituksimabom.
This is a cancer of the lymph tissue (part of the immune system) that affects a type of white blood cell called B lymphocytes, or B cells. 
To je rak limfnega tkiva (dela imunskega sistema), ki prizadene vrsto belih krvnih celic, imenovanih B-limfociti ali B-celice.
Other information about Pixuvri 
Druge informacije o zdravilu Pixuvri
Patients receiving Pixuvri must not be given vaccines containing attenuated (weakened live) viruses. 
Bolniki, ki se zdravijo z zdravilom Pixuvri, ne smejo dobiti cepiv z atenuiranimi (živimi oslabljenimi) virusi.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pixuvri. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Pixuvri, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.